Luminal B subtype is associated with high rate of tumor proliferation, among which HER2 negative Luminal B subtype is typically treated with endocrine therapy + chemotherapy; and HER2-positive Luminal B subtype is general treated with chemotherapy + anti-HER2 treatment + endocrine therapy. This evidence concerns the gene ERBB2 and neoplasm.